Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer (NCT06617923)
A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Who can join: Review the eligibility criteria below.
Location: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (410) 614-1361
Email: HopkinsGynTrials@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovary Cancer
- Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study — Knoxville, Tennessee
- Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) — Chicago, Illinois
- Multimedia Aid for Genetic Testing in Gynecologic Oncology — Chapel Hill, North Carolina
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib — Irvine, California
- Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy — Chicago, Illinois
Explore by condition: All Ovary Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.